The estimated Net Worth of Jama Pitman is at least $1.94 Миллион dollars as of 15 February 2024. Ms Pitman owns over 2,267 units of Deciphera Pharmaceuticals Inc stock worth over $1,740,913 and over the last 3 years she sold DCPH stock worth over $195,068.
Ms has made over 9 trades of the Deciphera Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 2,267 units of DCPH stock worth $35,411 on 15 February 2024.
The largest trade she's ever made was selling 2,267 units of Deciphera Pharmaceuticals Inc stock on 15 February 2024 worth over $35,411. On average, Ms trades about 1,219 units every 66 days since 2021. As of 15 February 2024 she still owns at least 68,031 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Ms Pitman stock trades at the bottom of the page.
Jama Pitman is the Sr. VP of Regulatory, Quality & Portfolio Management at Deciphera Pharmaceuticals Inc.
Ms Pitman is 42, she's been the Sr. VP of Regulatory и Quality & Portfolio Management of Deciphera Pharmaceuticals Inc since . There are 20 older and no younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Jama's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar и Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: